XML 488 R58.htm IDEA: XBRL DOCUMENT v3.25.4
Share-based compensation (Tables)
12 Months Ended
Dec. 31, 2025
Share-Based Payment Arrangement [Abstract]  
Schedule of share-based payment arrangement by share-based payment award, performance criteria The table below outlines the performance criteria and their respective weightings for the LTI performance plans
granted in 2025.
LTI performance plan criteria
Market/Non-market element
Weight
Relative TSR
Market
25%
Strategic value drivers
Non-market
35%
Technology Leadership Index
Non-market
20%
ESG measures
Non-market
20%
Total
100%
Following the US executive order 14173, the non-financial ESG performance metrics were modified as follows:
For the employees based in the US, the gender diversity performance measures are omitted, and an increased
weighting is applied on the Employee engagement and Inclusion score (13.33%), and
For the employees outside the US, the gender diversity performance measures are calculated excluding US
employees.
All employees who are eligible for the LTI plan 2023-2025 and 2024-2026 will be impacted by this modification. There
are no incremental fair value and no incremental compensation costs arising from the modifications.
Schedule of assumptions used for calculation of the fair value of shares The most important assumptions for the calculation of the fair value of shares for the LTI performance plans, which
include market-based performance criteria, are set out in this table:
Year ended December 31
2023
2024
2025
Share price in € at grant date
620.1
707.1
580.9
Expected volatility ASML
46.2%
40.0%
41.7%
Average volatility of the peer group
50.0%
43.3%
46.6%
Vesting period
2.9 years
2.9 years
2.7 years
Dividend yield
0.9%
0.7%
0.9%
Risk free interest rate (Eurozone)
2.4%
2.4%
1.8%
Risk free interest rate (US)
3.9%
4.2%
3.9%
Schedule of expenses for share plans An overview of the incurred and expected expenses for the LTI plans are set out in the following table:
Year ended December 31 (€, in millions)
2023
2024
2025
Incurred expenses
134.8
172.6
202.3
Expected expenses of conditionally granted plans in future periods
187.2
246.1
215.0
Weighted average period for recognizing these expected expenses
1.6 years
1.5 years
1.4 years
Recognized income tax benefit (excluding excess income tax benefits)
16.3
28.2
32.0
Schedule of shares activity during period Details with respect to shares granted and vested during the year are set out in the following table:
  
EUR-denominated
USD-denominated
Year ended December 31
2023
2024
2025
2023
2024
2025
Total fair value of shares vested during the year (in millions)
175.5
161.4
139.4
127.0
155.2
166.6
Weighted average fair value of shares granted
587.42
801.78
636.49
624.10
848.18
660.67
A summary of the status of conditionally outstanding shares as of December 31, 2025, and changes during the year
ended December 31, 2025, is presented below:
  
EUR-denominated
USD-denominated
 
Number
of shares
Weighted
average
fair value at
grant date
Number
of shares
Weighted
average
fair value at
grant date
Conditional shares outstanding at January 1, 2025
280,353
680.02
410,680
734.50
Granted
261,198
636.49
279,674
660.67
Vested
(203,871)
650.87
(229,822)
711.06
Forfeited
(6,314)
632.69
(13,191)
714.28
Conditional shares outstanding at December 31, 2025
331,366
664.54
447,341
700.98
Details with respect to stock options exercised and outstanding are set out in the following table:
  
EUR-denominated
USD-denominated
Year ended December 31
2023
2024
2025
2023
2024
2025
Weighted average share price at stock option exercise
613.03
834.48
722.84
678.41
911.23
840.14
Aggregate intrinsic value of exercised stock options (in millions)
8.1
10.2
8.8
4.8
8.2
6.8
Weighted average remaining contractual term of exercisable
options (in years)
1.48
0.83
0.32
1.43
0.84
0.30
Aggregate intrinsic value of exercisable stock options (in millions)
19.7
11.4
4.6
15.9
8.2
4.5
Aggregate intrinsic value of outstanding stock options (in millions)
19.7
11.4
4.6
15.9
8.2
4.5
Schedule of number and weighted average exercise prices of stock options activity The number and weighted average exercise prices of stock options as of December 31, 2025, and changes during the
year then ended are presented below:
  
 EUR-denominated
USD-denominated
 
Number
of options
Weighted
average exercise
price per ordinary
share (in €)
Number
of options
Weighted
average exercise
price per ordinary
share (in $)
Outstanding, January 1, 2025
19,336
87.48
13,734
95.58
Granted
Exercised
(13,779)
87.04
(9,090)
94.62
Forfeited
Expired
(78)
93.03
(1)
88.10
Outstanding, December 31, 2025
5,479
88.52
4,643
97.47
Exercisable, December 31, 2025
5,479
88.52
4,643
97.47
Schedule of range of exercise prices, number of outstanding options, and weighted average remaining contractual life of outsanding options Details with respect to stock options exercised in the relevant year and outstanding stock options as of December 31,
2025, are set out in the following table:
EUR-denominated
USD-denominated
Range of exercise
prices (in €)
Number of
outstanding options
Weighted average
remaining
contractual term of
outstanding (years)
Range of exercise
prices (in $)
Number of
outstanding options
Weighted average
remaining
contractual term of
outstanding (years)
8090
3,569
0.19
8090
0.00
90100
1,910
0.56
90100
2,976
0.15
100110
0.00
100110
1,667
0.56
Total
5,479
0.32
Total
4,643
0.30